Follow the people · Insider
Third Rock Ventures V, L.P.
Third Rock Ventures V, L.P. files insider transactions with the SEC as a 10% owner of Septerna (SEPN). We hold 6 disclosed purchases and sales filed since 10 June 2024, 1 of them in the last 90 days.
- Files forSEPN
- Disclosed buys and sells6 in all, 1 in the last 90 days
- Last disclosure14 August 2026
Positions held
2 posts we hold — a term names its own dates; a run of filings only says when they filed- Filed 12 August 2026 — 12 August 202610% owner · Septerna (SEPN)2 Form 4 lines · source: SEC Form 4
- Filed 10 June 2024 — 26 May 202610% owner · Rapport Therapeutics (RAPP)10 Form 4 lines · source: SEC Form 4
Everything they disclosed
12 entries, newest first — one per disclosure report, one per Form 4 line- ▼ sold on the open market 147,059 shares of SepternaSEC Form 414 August 2026Common Stock · traded 12 August 2026 · filed 14 August 2026
- ▼ sold on the open market 141 shares of SepternaSEC Form 414 August 2026Common Stock · traded 12 August 2026 · filed 14 August 2026
- ▼ sold on the open market 18,572 shares of Rapport TherapeuticsSEC Form 428 May 2026Common Stock · traded 26 May 2026 · filed 28 May 2026
- ▼ sold on the open market 133,618 shares of Rapport TherapeuticsSEC Form 413 May 2026Common Stock · traded 11 May 2026 · filed 13 May 2026
- ▼ sold on the open market 271,495 shares of Rapport TherapeuticsSEC Form 411 May 2026Common Stock · traded 7 May 2026 · filed 11 May 2026
- ▼ sold on the open market 5,018 shares of Rapport TherapeuticsSEC Form 411 May 2026Common Stock · traded 8 May 2026 · filed 11 May 2026
- ▼ sold on the open market 426,005 shares of Rapport TherapeuticsSEC Form 421 April 2026Common Stock · traded 17 April 2026 · filed 21 April 2026
- converted 56,091,177 shares of Rapport Therapeutics (a derivative holding)SEC Form 410 June 2024Series A Preferred Stock · traded 10 June 2024 · filed 10 June 2024
- converted 8,000,000 shares of Rapport Therapeutics (a derivative holding)SEC Form 410 June 2024Series A Preferred Stock · traded 10 June 2024 · filed 10 June 2024
- converted 298,103 shares of Rapport Therapeutics (a derivative holding)SEC Form 410 June 2024Series B Preferred Stock · traded 10 June 2024 · filed 10 June 2024
- converted 6,551,449 shares of Rapport TherapeuticsSEC Form 410 June 2024Common Stock · traded 10 June 2024 · filed 10 June 2024
- converted 969,218 shares of Rapport TherapeuticsSEC Form 410 June 2024Common Stock · traded 10 June 2024 · filed 10 June 2024
Positions come from the unitedstates/congress-legislators roster, the Office of Government Ethics and the SEC’s Form 4 index. Every disclosed line names its own source and links the document the government published; we print what the filing says and never a price we did not read from it. Headlines and links come from the GDELT Global Knowledge Graph — the story stays with the publisher. The portrait, where we have one, is the public-domain Congressional Bioguide photograph.